First three neisseria gonorrhoeae isolates with high-Level resistance to azithromycin in sweden: A threat to currently available dual-Antimicrobial regimens for treatment of gonorrhea?

摘要

Neisseriagonorrhoeaehas developed resistance to all antimicrobials previously used for first-line treatment of gonorrhea (1). Treatment failures with the extended-spectrum cephalosporins (ESCs) cefixime and ceftriaxone, the only remaining antimicrobials for monotherapy in most countries, have now emerged in several countries (2-5). Consequently, in the United States (6) and Europe (7), dual-antimicrobial therapies recommending ceftriaxone (250 to 500 mg [one dose]) together with azithromycin (1 to 2 g [one dose]) have been introduced.